Turnidge John D, Gottlieb Thomas, Mitchell David H, Coombs Geoffrey W, Pearson Julie C, Bell Jan M
Microbiology and Infectious Diseases, SA Pathology, Women's and Children's Hospital, North Adelaide, South Australia and Departments of Pathology, Paediatrics and Molecular Biosciences, University of Adelaide, South Australia.
Department of Microbiology and Infectious Diseases, Concord, Concord, New South Wales.
Commun Dis Intell Q Rep. 2014 Mar 31;38(1):E49-53. doi: 10.33321/cdi.2014.38.10.
The Australian Group on Antimicrobial Resistance performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2011 survey focussed on hospital-onset infections, examining isolates from all specimens presumed to be causing disease. In 2011, 1,827 Escherichia coli, 537 Klebsiella species and 269 Enterobacter species were tested using a commercial automated method (Vitek 2, BioMérieux) and results were analysed using Clinical and Laboratory Standards Institute breakpoints from January 2012. Of the key resistances, non-susceptibilty to the third-generation cephalosporin, ceftriaxone, was found in 9.6% of E. coli and 9.5%-12.1% of Klebsiella spp. Non-susceptibility rates to ciprofloxacin were 10.6% for E. coli, 0.0%-8.3% for Klebsiella spp. and 0.0%-5.0% in Enterobacter spp. Resistance rates to gentamicin were 8.6%, 2.9%-10.9%, and 0.0%-15.6% for the same 3 groups respectively. Eight strains, 5 Klebsiella spp. and 3 Enterobacter spp. were shown to harbour a carbapenemase (IMP-4).
澳大利亚抗菌药物耐药性研究小组定期开展时期患病率研究，以监测特定肠道革兰氏阴性病原体的抗菌药物耐药性变化。2011年的调查聚焦于医院感染，检查了所有疑似致病标本中的分离株。2011年，使用商业自动化方法（Vitek 2，生物梅里埃公司）对1827株大肠杆菌、537株克雷伯菌属和269株肠杆菌属进行了检测，并采用临床和实验室标准协会2012年1月起的标准对结果进行分析。在主要耐药情况中，第三代头孢菌素头孢曲松的非敏感性在9.6%的大肠杆菌和9.5%-12.1%的克雷伯菌属中被发现。大肠杆菌对环丙沙星的非敏感性率为10.6%，克雷伯菌属为0.0%-8.3%，肠杆菌属为0.0%-5.0%。上述三组对庆大霉素的耐药率分别为8.6%、2.9%-10.9%和0.0%-15.6%。有8株菌株（5株克雷伯菌属和3株肠杆菌属）被证明携带碳青霉烯酶（IMP-4）。
